Moderna’s stock jumps 6% as its cancer vaccine could treat more than just melanoma

Moderna’s stock got a boost on Tuesday after positive data was released from a trial of a form of head-and-neck cancer.

Previous post States sue over Biden’s student-loan repayment program using arguments that succeeded before
Next post A crucial report Wednesday is expected to show little progress against inflation